(Q40518920)

21 September 2017

Dynamics of Epstein-Barr viral load after hematopoietic stem cell transplantation and effect of preemptive rituximab therapy (English)

1 reference

21 September 2017

1 reference

1 reference

Mihaja Raberahona

1

1 reference

21 September 2017

Chloe Wackenheim

2

1 reference

21 September 2017

Raphaele Germi

3

1 reference

21 September 2017

Martin Carré

4

1 reference

21 September 2017

Claude-Eric Bulabois

5

1 reference

21 September 2017

Anne Thiébaut

6

1 reference

21 September 2017

Julien Lupo

7

1 reference

21 September 2017

Touyana Semenova

8

1 reference

21 September 2017

Jean-Yves Cahn

9

1 reference

21 September 2017

Patrice Morand

10

1 reference

21 September 2017

Olivier Epaulard

11

1 reference

21 September 2017

1 October 2016

1 reference

Transplant Infectious Disease

21 September 2017

1 reference

21 September 2017

18

1 reference

21 September 2017

6

1 reference

21 September 2017

889-895

1 reference

The curious case of the tumour virus: 50 years of Burkitt's lymphoma

21 September 2017

1 reference

The pathogenesis of Epstein-Barr virus persistent infection.

21 January 2018

1 reference

Epstein-Barr virus and virus human protein interaction maps

21 January 2018

1 reference

Gammaherpesvirus and lymphoproliferative disorders in immunocompromised patients

21 January 2018

1 reference

Epstein-Barr virus lymphoproliferative disease after hematopoietic stem cell transplant

21 January 2018

1 reference

The tumor virus landscape of AIDS-related lymphomas

21 January 2018

1 reference

How I treat EBV lymphoproliferation

21 January 2018

1 reference

Real-time quantitative PCR for assessment of antiviral drug effects against Epstein-Barr virus replication and EBV late mRNA expression

21 January 2018

1 reference

Incidence, kinetics, and risk factors of Epstein-Barr virus viremia in pediatric patients after allogeneic stem cell transplantation

21 January 2018

1 reference

The clinical value of concomitant Epstein Barr virus (EBV)-DNA load and specific immune reconstitution monitoring after allogeneic hematopoietic stem cell transplantation.

21 January 2018

1 reference

Monitoring of Epstein-Barr virus load after hematopoietic stem cell transplantation for early intervention in post-transplant lymphoproliferative disease

21 January 2018

1 reference

A prospective study of Epstein-Barr virus load in 85 hematopoietic stem cell transplants

21 January 2018

1 reference

Prognostic factors and outcome of Epstein-Barr virus DNAemia in high-risk recipients of allogeneic stem cell transplantation treated with preemptive rituximab

21 January 2018

1 reference

Lytic and latent EBV gene expression in transplant recipients with and without post-transplant lymphoproliferative disorder.

21 January 2018

1 reference

Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia

21 January 2018

1 reference

Features of Epstein-Barr Virus (EBV) reactivation after reduced intensity conditioning allogeneic hematopoietic stem cell transplantation.

21 January 2018

1 reference

Increased infection rate after preemptive rituximab treatment for Epstein-Barr virus reactivation after allogeneic hematopoietic stem-cell transplantation

21 January 2018

1 reference

Monitoring of Hepatitis B Virus (HBV) DNA and Risk of HBV Reactivation in B-Cell Lymphoma: A Prospective Observational Study

21 January 2018

1 reference

Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: analysis from the Asia Lymphoma Study Group

21 January 2018

1 reference

Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections.

21 January 2018

1 reference

Subcutaneous immunoglobulin in lymphoproliferative disorders and rituximab-related secondary hypogammaglobulinemia: a single-center experience in 61 patients.

21 January 2018

1 reference

EBV-associated post-transplant lymphoproliferative disorder following in vivo T-cell-depleted allogeneic transplantation: clinical features, viral load correlates and prognostic factors in the rituximab era.

21 January 2018

1 reference

Impact of Epstein Barr virus-related complications after high-risk allo-SCT in the era of pre-emptive rituximab.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/TID.12618

1 reference

21 September 2017

1 reference